Sysmex (OTCMKTS:SSMXY) Shares Gap Up – What’s Next?

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped up before the market opened on Friday . The stock had previously closed at $8.37, but opened at $8.8750. Sysmex shares last traded at $8.8750, with a volume of 530 shares trading hands.

Analyst Ratings Changes

Separately, Citigroup downgraded shares of Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Sysmex has an average rating of “Hold”.

Sysmex Trading Up 7.8%

The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The firm has a market cap of $5.68 billion, a price-to-earnings ratio of 23.74 and a beta of 1.10. The company has a fifty day moving average price of $8.71 and a 200-day moving average price of $9.10.

Sysmex (OTCMKTS:SSMXY) last posted its earnings results on Thursday, May 14th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). The company had revenue of $877.92 million for the quarter, compared to analyst estimates of $862.45 million. Sysmex had a return on equity of 7.23% and a net margin of 7.13%.Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, research analysts expect that Sysmex Corporation ADR will post 0.42 EPS for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.